What's next and the MS Investor conference Tuesday
It is a nice summary of the conference call. Commenting on your Item 1), I also speculated that ALS 2200 must be looking for a partner drug in BMY's NS5A inhibitor. What else is there internally or externally to match the potential safety and efficacy of 2200? Ian also echoed the confidence in the safety of 2200, expressed first by Peter during the July 30 CC. However, RBV or 222 or TVR also holds the key to make a cocktail for an 8 week treatment regimen that Ian talked about. If BMY agrees to partner with VRTX, guess where the share price is going to be.